E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Novartis Meningococcal ABCWY conjugate vaccine is intended for
prevention of meningitis and septicemia caused by Neisseria
meningitidis serogroups A, B, C, W and Y. |
|
E.1.1.1 | Medical condition in easily understood language |
Novartis Meningococcal ABCWY conjugate vaccine is intended for
prevention of meningitis and septicemia caused by Neisseria
meningitidis serogroups A, B, C, W and Y. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the effectiveness of the MenABCWY vaccine against a randomly selected panel of endemic US N. meningitidis
serogroup B invasive disease strains as measured by bactericidal activity at 1:4 dilution using enc-hSBA at one month after the
3-dose series, when compared to a single dose of MenACWY. |
|
E.2.2 | Secondary objectives of the trial |
1 Safety, reactogenicity 3rd dose MenABCWY.
2 Effectiveness MenABCWY against MenB: bactericidal activity 1:4 dilution, enc-hSBA, 4 months, 3 doses.
3 Effectiveness MenABCWY against MenB: bactericidal activity 1:8 dilution, enc-hSBA 1, 4 months, 3 doses.
4 Effectiveness MenABCWY against MenB: bactericidal activity 1:4 and 1:8 dilution, enc-hSBA 1, 4 months, 3 doses.
5 Distribution of subjects by % MenB strains killed at 1:4 and 1:8 dilutions, enc-hSBA 1, 4 months, 3 doses.
6 Immunogenicity MenABCWY against MenB: % subjects with enc-hSBA titer ≥ 4 and ≥ 8 1, 4 months, 3 doses.
7 Immunogenicity MenABCWY against MenB: hSBA GMTs, % subjects with hSBA titers ≥ LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 and % subjects with 2-, 3- and 4-fold rise in hSBA titer 1, 4 months, 3 doses.
8 Immunogenicity MenABCWY against MenA, C, W, Y: hSBA GMTs, % subjects with hSBA titers ≥LLQ, ≥ 8, ≥ 16, ≥ 32, ≥ 64, ≥128 and % subjects with 2-, 3- and 4-fold rise in hSBA titer 1, 4 months, 3 doses. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Adolescents who completed V102_16 study and received the study vaccines as assigned in the protocol (either two doses of the MenABCWY or one dose each of MenACWY and Placebo). |
|
E.4 | Principal exclusion criteria |
1) Serious, acute, or chronic illnesses. Previous or suspected disease caused by N. meningitidis.
2) History of any meningococcal vaccine administration other than vaccination given in the parent V102_16 protocol. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1) The percentage of subjects without bactericidal serum activity at 1:4 dilution using enc-hSBA against each of the endemic US N. meningitidis serogroup B strains. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Day 31, 1 month after the 3-dose vaccination series |
|
E.5.2 | Secondary end point(s) |
1) Percentages of subjects without bactericidal activity at 1:4 dilution against each US N. meningitidis serogroup B strain at 4 months after 3 doses.
2) Percentages of subjects without bactericidal activity at 1:8 dilution against each US N. meningitidis serogroup B strain at 1 and 4
months after 3 doses.
3) Percentages of strains with VE values corresponding to predefined effectiveness ranges at 1:4 dilution at 1 month after 3 doses.
4) Percentages of strains with VE values corresponding to predefined effectiveness ranges at 1:4 dilution at 4 months after 3 doses.
5) Percentages of strains with VE values corresponding to predefined effectiveness ranges at 1:8 dilution at 1 month after 3 doses.
6) Percentages of strains with VE values corresponding to predefined effectiveness ranges at 1:8 dilution at 4 months after 3 doses.
7) Percentage of US N. meningitidis serogroup B strains killed at 1:4 and 1:8 dilutions at 1 and 4 months after 3 doses.
8) Percentage of subjects with enc-hSBA ≥ 1:4 and enc-hSBA ≥ 1:8 1 and 4 months after 3 doses.
9) hSBA Geometric Mean Titers (GMTs) against the N. meningitidis serogroup B test strains.
10) Percentages of subjects with hSBA titers against N. meningitidis serogroup B test strains ≥ Lower Limit of Quantitation (LLQ) at 1
and 4 months after 3 doses.
11) Percentages of subjects with a four-fold rise in hSBA titer against the N. meningitidis serogroup B test strains at 1 and 4 months after
3 doses.
12) hSBA GMTs against N. meningitidis serogroups A, C, W and Y.
13) Percentages of subjects with hSBA titers against the N. meningitidis serogroup A, C, W and Y ≥ LLQ at 1 and 4 months after 3 doses.
14) Percentages of subjects with a four-fold rise in hSBA titer against the N. meningitidis serogroup B test strains at 1 and 4 months after
3 doses.
15) Number of subjects reporting any solicited local or systemic Adverse Events (AEs).
16) Number of subjects reporting unsolicited AEs after any vaccination.
17) Number of subjects reporting any serious AEs (SAEs), medically-attended AEs and AEs leading to premature withdrawal. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1) 4 months after 3 doses
2) 1 and 4 months after 3 doses
3) 1 month after 3 doses
4) 4 months after 3 doses
5) 1 month after 3 doses
6) 4 months after 3 doses
7) 1 and 4 months after 3 doses
8) 1 and 4 months after 3 doses
9) 1 and 4 months after 3 doses
10) 1 and 4 months after 3 doses
11) 1 and 4 months after 3 doses
12) hSBA GMTs against N. meningitidis serogroups A, C, W and Y.
13) 1 and 4 months after 3 doses
14) 1 and 4 months after 3 doses
15) Day 1 (6 hours) to Day 7 after vaccination
16) Day 1 to Day 30 after any vaccination
17) Entire study period |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Evaluation of primary and secondary objectives requires the testing of biological samples from the study subjects, which can only be completed after all samples are collected. The last samples for the analysis of the secondary immunogenicity objectives will be taken at the last study visit. For the purpose of this study, end of trial is defined as the completion of the testing of such biological samples, to be achieved no later than 8 months after collection of the last biological sample visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |